Herpes simplex
☆ I le 2022 Stiftung Warentest i'uga mai Siamani, o le fa'amalieina o tagata fa'atau i ModelDerm sa na'o sina maualalo ifo nai lo fa'atalanoaga telemedicine totogi.
Herpes simplex ile laugutu.
Herpes simplex ― O le fa'ama'i o le herpes simplex i tamatamai lima e sili atu ona taatele i tamaiti laiti nai lo tagata matutua.
References
Ole fa'ama'i ole HSV-1 e fa'asolosolo ile fa'ama'i muamua ole sela epithelial, soso'o ai ma le fa'aletonu, aemaise ile neu, ma le toe fa'afouina. O le HSV-1 e masani lava ona fa'atupuina fa'amata'u ma fa'aoso fa'aoso, fa'atupu i le gutu ma le mucosa o le itutinosa. O ona fa'aaliga e afua mai i le orolabial herpes i tulaga eseese e pei o le herpetic folliculitis, fa'ama'i pipisi o le pa'u, a'afiaga o mata, ma tulaga ogaoga e pei o le herpes encephalitis. O togafitiga fa'ama'i e fesoasoani e pulea fa'ama'i HSV.
Herpes simplex virus type 1 (HSV-1) is a member of the Alphaherpesviridae subfamily. Its structure is composed of linear dsDNA, an icosahedral capsid that is 100 to 110 nm in diameter, with a spikey envelope. In general, the pathogenesis of HSV-1 infection follows a cycle of primary infection of epithelial cells, latency primarily in neurons, and reactivation. HSV-1 is responsible for establishing primary and recurrent vesicular eruptions, primarily in the orolabial and genital mucosa. HSV-1 infection has a wide variety of presentations, including orolabial herpes, herpetic sycosis (HSV folliculitis), herpes gladiatorum, herpetic whitlow, ocular HSV infection, herpes encephalitis, Kaposi varicelliform eruption (eczema herpeticum), and severe or chronic HSV infection. Antiviral therapy limits the course of HSV infection.
Herpes simplex virus type 1 (HSV-1) is a member of the Alphaherpesviridae subfamily. Its structure is composed of linear dsDNA, an icosahedral capsid that is 100 to 110 nm in diameter, with a spikey envelope. In general, the pathogenesis of HSV-1 infection follows a cycle of primary infection of epithelial cells, latency primarily in neurons, and reactivation. HSV-1 is responsible for establishing primary and recurrent vesicular eruptions, primarily in the orolabial and genital mucosa. HSV-1 infection has a wide variety of presentations, including orolabial herpes, herpetic sycosis (HSV folliculitis), herpes gladiatorum, herpetic whitlow, ocular HSV infection, herpes encephalitis, Kaposi varicelliform eruption (eczema herpeticum), and severe or chronic HSV infection. Antiviral therapy limits the course of HSV infection.
Herpes simplex virus type 2 (HSV-2) ose fa'ama'i pipisi tele, e a'afia ai le tusa ma le 22% o tagata matutua e 12 tausaga ma luga atu, e tusa ma le 45 miliona tagata matutua i le Iunaite Setete. E ui o le HSV-1 e masani ona mafua ai le ma'i o le gutu, e mafai fo'i ona o'o atu ai i manu'a i le itutinosa. Ae peita'i, pe a maua e tagata ma'i ni manu'a i le itutinosa, o le HSV-2 e masani lava o le popolega autu. O fa'ailoga o le fa'ama'i o le HSV-2 e masani ona le manino, e pei o le ma'i o le itutino ma le ita, lea e mafai ona fa'atuai ai su'esu'ega ma togafitiga. O lenei tuai e ono i'u atu ai i isi fa'asalalauga i tagata e le'i pisia.
Herpes simplex virus type 2 (HSV-2) continues to be a common infection, affecting approximately 22% of adults ages 12 and older, representing 45 million adults in the United States alone. While HSV-1 often affects the perioral region and can be known to cause genital lesions, HSV-2 is more commonly the consideration when patients present with genital lesions. Despite this, most outbreaks of the infection will present with nonspecific symptoms such as genital itching, irritation, and excoriations, which may cause diagnosis and treatment to be delayed. As a result, further exposure to uninfected individuals may occur.
Herpes simplex virus type 2 (HSV-2) continues to be a common infection, affecting approximately 22% of adults ages 12 and older, representing 45 million adults in the United States alone. While HSV-1 often affects the perioral region and can be known to cause genital lesions, HSV-2 is more commonly the consideration when patients present with genital lesions. Despite this, most outbreaks of the infection will present with nonspecific symptoms such as genital itching, irritation, and excoriations, which may cause diagnosis and treatment to be delayed. As a result, further exposure to uninfected individuals may occur.
Herpes simplex virus (HSV) e masani ona fa'atupu fa'ama'i e pei o le fa'ama'i toto ma le ma'alili i tupulaga ma tagata matutua. Pe a a'afia e le HSV se pepe i totonu o le 4-6 vaiaso muamua o le olaga, e mafai ona i'u ai i ma'i tuga ma i'uga tuga. Ole su'esu'eina vave ole fa'ama'i o le HSV pepe fou e taua tele e taofia ai le fa'atupuina o le fa'ama'i, puipuia ai fa'afitauli o le neura (e o'o lava i le oti) .
Herpes simplex virus (HSV), a member of the Herpesviridae family, is a well-known cause of infections including genital herpes and herpes labialis in the adolescent and adult population. Transmission of HSV infection to an infant during the first 4-6 weeks of life can lead to devastating disease with the potential for poor outcomes. Early diagnosis is imperative when evaluating neonatal HSV infection in order to prevent further disease progression, neurological complications, and even death.
Herpes simplex virus (HSV), a member of the Herpesviridae family, is a well-known cause of infections including genital herpes and herpes labialis in the adolescent and adult population. Transmission of HSV infection to an infant during the first 4-6 weeks of life can lead to devastating disease with the potential for poor outcomes. Early diagnosis is imperative when evaluating neonatal HSV infection in order to prevent further disease progression, neurological complications, and even death.
Herpes simplex fa'ama'i e taatele ma e mafai ona pasi mai fafine ma'itaga i a latou pepe. O lenei virus e mafai ona mafua ai ni fa'afitauli ogaoga o le soifua maloloina po'o le oti fo'i i pepe fou. E ui e seasea i le taimi o le maitaga lava ia, ae masani ona tupu i le taimi o le fanauina. E sili atu le tulaga lamatia pe a a'afia le tina i vaega mulimuli o le maitaga. Ae ui i lea, e mafai ona faʻaitiitia lenei lamatiaga e ala i le faʻaaogaina o vailaʻau antiviral poʻo le filifili mo se C-vaega i nisi tulaga.
Infection with herpes simplex is one of the most common sexually transmitted infections. Because the infection is common in women of reproductive age it can be contracted and transmitted to the fetus during pregnancy and the newborn. Herpes simplex virus is an important cause of neonatal infection, which can lead to death or long-term disabilities. Rarely in the uterus, it occurs frequently during the transmission delivery. The greatest risk of transmission to the fetus and the newborn occurs in case of an initial maternal infection contracted in the second half of pregnancy. The risk of transmission of maternal-fetal-neonatal herpes simplex can be decreased by performing a treatment with antiviral drugs or resorting to a caesarean section in some specific cases.
Infection with herpes simplex is one of the most common sexually transmitted infections. Because the infection is common in women of reproductive age it can be contracted and transmitted to the fetus during pregnancy and the newborn. Herpes simplex virus is an important cause of neonatal infection, which can lead to death or long-term disabilities. Rarely in the uterus, it occurs frequently during the transmission delivery. The greatest risk of transmission to the fetus and the newborn occurs in case of an initial maternal infection contracted in the second half of pregnancy. The risk of transmission of maternal-fetal-neonatal herpes simplex can be decreased by performing a treatment with antiviral drugs or resorting to a caesarean section in some specific cases.
Herpes simplex virus (HSV) ituaiga 1 ma le 2 ua aafia ai le tele o tagata i le lalolagi atoa. E masani lava, e nofo filemu le siama i totonu o sela neura pe a uma ona afaina le paʻu, ae mafai ona toe faʻafouina mulimuli ane, ma mafua ai le malulu. O nisi taimi, e o'o atu ai i fa'afitauli ogaoga e pei o fa'ama'i mata, fula o fai'ai, po'o tulaga mata'utia i pepe fou ma tagata e vaivai le puipuiga. E ui o vaila'au o lo'o iai nei e fesoasoani e pulea fa'ama'i pipisi, o le lamatiaga o le tete'e o vaila'au ma a'afiaga o lo'o tumau pea le popolega. Matou te manaʻomia ni vailaʻau fou e taulaʻi lelei ai le siama.
Infection with herpes simplex virus (HSV) types 1 and 2 is ubiquitous in the human population. Most commonly, virus replication is limited to the epithelia and establishes latency in enervating sensory neurons, reactivating periodically to produce localized recurrent lesions. However, these viruses can also cause severe disease such as recurrent keratitis leading potentially to blindness, as well as encephalitis, and systemic disease in neonates and immunocompromised patients. Although antiviral therapy has allowed continual and substantial improvement in the management of both primary and recurrent infections, resistance to currently available drugs and long-term toxicity pose a current and future threat that should be addressed through the development of new antiviral compounds directed against new targets.
Infection with herpes simplex virus (HSV) types 1 and 2 is ubiquitous in the human population. Most commonly, virus replication is limited to the epithelia and establishes latency in enervating sensory neurons, reactivating periodically to produce localized recurrent lesions. However, these viruses can also cause severe disease such as recurrent keratitis leading potentially to blindness, as well as encephalitis, and systemic disease in neonates and immunocompromised patients. Although antiviral therapy has allowed continual and substantial improvement in the management of both primary and recurrent infections, resistance to currently available drugs and long-term toxicity pose a current and future threat that should be addressed through the development of new antiviral compounds directed against new targets.
E lua ituaiga o herpes simplex virus, ituaiga 1 (HSV-1) ma le ituaiga 2 (HSV-2). O le HSV-1 e masani ona fa'atupu fa'ama'i pipisi ile gutu ae ole HSV-2 e fa'atupu fa'ama'i toto'a. E feavea'i e ala i fesootaiga tuusao ma le tagata ua aafia. Ua fa'avasegaina fa'ama'i fa'afeusuaiga. E mafai ona sosolo atu i se pepe i le taimi e fanau ai. A mae'a fa'ama'i, e fe'avea'i fa'ama'i i neura fa'alogo i tino sela o neura, lea e nonofo ai i le olaga atoa. O mafua'aga o le toe tupu e ono aofia ai: fa'aitiitia le fa'aogaina o le puipuiga, fa'alavelave, ma le susulu o le la.
I le tele o tulaga, e na'o le inuina o vaila'au antiviral pe a ogaoga fa'ailoga. O vaila'au fa'ama'i fa'ama'i i aso ta'itasi e mafai ona fa'atonuina i se tasi e tele fa'ama'i pipisi. E leai se tui e maua ma e le mafai e le tui shingles ona puipuia le herpes simplex. O togafitiga fa'atasi ai ma vaila'au fa'ama'i e pei ole aciclovir po'o le valaciclovir e mafai ona fa'aitiitia ai le ogaoga o fa'ailoga.
Ole fua ole HSV-1 po'o le HSV-2 ile lalolagi atoa ole va ole 60% ma le 95% i tagata matutua. E masani ona a'afia le HSV-1 a'o laiti. E tusa ma le 536 miliona tagata i le lalolagi atoa (16% o le faitau aofaʻi) na aʻafia i le HSV-2 e pei o le 2003 ma e sili atu le aofaʻi i fafine ma i latou o loʻo i le lalolagi atiaʻe. O le tele o tagata e maua i le HSV-2 latou te le iloa o lo'o a'afia i latou.
○ Togafitiga ― OTC Drugs
Aloese mai so'o se fa'afeso'ota'iga fa'aletino, e pei o le sogi i se tamaititi, a'o iai le ma'i ma'i, ona o le fa'afeso'ota'i e mafai ona sosolo atu ai le fa'ama'i i isi tagata. E tatau ona e malolo e aunoa ma le inu ava malosi.
#Acyclovir cream